Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS Total Liabilities

Everything the company owes to creditors and other parties.

Cellectis S.A.NASDAQ: CLLS

Total Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total liabilities falls 7.5% from a year ago

Total liabilities stood at $229.27M at the end of Q1 FY2026, down 7.5% from a year earlier and down 7.9% from the prior quarter. Over 3 fiscal years it compounded at +22.5% a year.

Context

  • Total liabilities amounted to 79.3% of total assets at the end of Q1 FY2026, up 11.2 pp from a year earlier.
  • Total liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total liabilities keeps falling in the next quarterly balance sheet after a -7.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$229.27M-7.9% QoQ
Last fiscal yearDec 2025
$248.82M-1.5% YoY
Year agoMar 2025
$247.88M-7.5% since
Total Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.5%——
1 year-1.5%——
3-year CAGR+22.5%——
5-year CAGR——
10-year CAGR——

Total Liabilities history

USD · from the balance sheet

Latest · FY2025
248.82M USD
Year-over-year change
-1.5%
4-year CAGR
+14.3%

Total Liabilities vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -7.5% is the 7th highest of 11, against a peer median of +0.7%.
  • Total liabilities amounts to 79.3% of total assets for CLLS, versus a peer median of 32.6%.
CLLS Competitors
Total Liabilities for CLLS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026$229.27M USD-7.5%+22.5%79.3%
AMRNAmarin Corporation plcMar 2026$196.35M USD+7.9%-10.1%30.4%
ACIUAC Immune S.A.Mar 2026CHF 105.89M CHF-8.9%+86.2%77.1%
SLNSilence Therapeutics plcMar 2026$65.72M USD-77.9%-6.8%57.1%
KRROKorro Bio, Inc.Mar 2026$63.99M USD+1.2%-28.9%34.8%
DBVTDBV Technologies S.A.Mar 2026$58.5M USD+22.7%+7.6%22.0%
LRMRLarimar Therapeutics, Inc.Mar 2026$50.48M USD+94.9%+63.5%24.2%
DRTSAlpha Tau Medical Ltd.Mar 2026$39.42M USD+60.2%+26.7%36.2%
ANROAlto Neuroscience, Inc.Mar 2026$32.89M USD+0.2%-27.8%11.9%
ALDXAldeyra Therapeutics, Inc.Mar 2026$24.33M USD-17.8%-2.8%36.6%
MREOMereo BioPharma Group plcMar 2026$6.56M USD-20.4%-42.3%16.2%
Peer median (excluding CLLS) —+0.7%-4.8%32.6%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents185.64M89.79M136.71M143.25M63.58M
Short-term Investments499K7.91M67.11M117.06M145.08M
Net Receivables31.07M17.57M23.13M23.04M25.32M
Inventory00000
Other Current Assets50K22.31M345K298K329K
Total Current Assets225.43M143.81M233.01M287.07M236.24M
Property, Plant & Equipment (Net)148.27M107.9M92.74M75.86M62.45M
Goodwill00000
Intangible Assets1.85M718K672K1.12M535K
Long-term Investments6.52M8.79M7.85M7.52M5.09M
Tax Assets000382K382K
Other Non-current Assets3K0(1K)11.6M20.03M
Total Non-current Assets156.65M117.41M101.27M96.48M88.48M
Total Assets382.08M261.22M334.27M383.54M324.72M
Account Payables23.76M21.46M19.07M18.66M17.28M
Short-term Debt2.25M4.97M5.16M4.84M18.16M
Tax Payables71K3.06M016K0
Deferred Revenue301K59K110.33M112.16M96.8M
Other Current Liabilities2.16M16.16M2.72M13.37M13.51M
Total Current Liabilities49.35M63M155.14M166.27M145.75M
Long-term Debt18.77M13.57M28.44M43.99M74.01M
Deferred Tax Liabilities00158K00
Deferred Revenue (Non-current)00000
Other Non-current Liabilities5.96M9.35M22.88M17.02M1.33M
Total Non-current Liabilities96.25M72.28M94.43M95.25M103.07M
Total Liabilities145.6M135.28M249.58M252.51M248.82M
Common Stock2.95M2.96M4.37M5.89M5.9M
Retained Earnings(698.33M)(439.5M)(405.77M)(329.61M)(334.13M)
Accumulated OCI(18.02M)(28.61M)(36.69M)(39.54M)(33.32M)
Other Stockholders Equity(1K)01K00
Minority Interest15.18M7.97M000
Total Equity236.47M125.94M84.7M131.03M75.9M
Total Debt100.87M75.77M85.06M91.46M119.9M
Net Debt(84.77M)(14.02M)(51.65M)(51.79M)56.32M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.